Claudia Adams Barr Program in Innovative Cancer Research Dana-Farber Cancer Institute BARR PROGRAM IMPACT STATEMENTS

Size: px
Start display at page:

Download "Claudia Adams Barr Program in Innovative Cancer Research Dana-Farber Cancer Institute BARR PROGRAM IMPACT STATEMENTS"

Transcription

1 Claudia Adams Barr Program in Innovative Cancer Research Dana-Farber Cancer Institute BARR PROGRAM IMPACT STATEMENTS Brain Cancer New Treatment Opportunities - Discovery of new pathways in brain cancers leading directly to promising new clinical trials for the nearly 23,000 patients who develop these diseases every year. Brain cancers remain one of the most difficult cancers to treat and are responsible for more than 13,000 deaths annually. Barr Program support in and enabled Rosalind Segal, MD, PhD, to discover that a genetic pathway called Notch is consistently damaged in brain tumors. Drugs already exist for other diseases to target Notch, and exciting new clinical trials are now underway to explore opportunities to use these drugs for people with brain cancers. This has the potential to significantly improve survival for these devastating cancers. Breast Cancer Discovering New Treatments - Explaining how drugs like Tamoxifen have improved breast cancer survival rates by 33% in significant numbers of women, leading to the possible discovery of additional treatments with even better outcomes for people with breast cancer. Myles Brown, MD, used Barr funding in to make the first genome-wide map of all genes that estrogen controls. This has enabled scientists for the first time to understand why certain drugs have been so effective in treating breast cancer, including the marked improvement in survival for women whose breast cancers respond to tamoxifen and other drugs that block estrogen. Dr. Brown s work is now expected to lead to new drugs and treatments for cancers that target critical pathways in breast cancer. His team has used this information to discover new ways to treat breast cancers that don t respond to Tamoxifen. Inhibiting Cancer Cell Growth - Discovery of a critically important biochemical pathway in breast cancer cells leading to the development of inhibitors of this pathway and the potential to significantly impact cancer growth. Dr. Jean Zhao s Barr funding in 2004 allowed her to systematically test a large number of proteins for their effects on breast cancer growth. She identified a critically important role for the protein PIK3CA in the behavior of breast cancer cells in the 36% of women whose breast cancers have this mutation. Several drug companies have now developed PIK3CA inhibitors that are being tested in clinical trials of breast and other cancers, and are showing great promise.

2 Cancer Genetics Enabling Meaningful Analysis of Massive Databases - Identification of new methods for controlling cancer cell growth, especially in breast and prostate cancers, by allowing scientists around the world to interpret huge databases of gene expression data. The Human Genome Project and DNA technology in general have provided the important tools needed to uncover and treat the genetic abnormalities that cause cancer. Since there are three billion units of DNA in the genome and an unknown number of ways that their functions are controlled, the technologies used for research on the genetics of cancer are creating a tsunami of data. Awarded Barr funding in 2005, Shirley (Xiaole) Liu, PhD, conducted groundbreaking research to provide a way to manage that data. Scientists around the world are now using Dr. Liu s open source techniques, uncovering new pathways toward cancer development that can be targeted by novel and effective therapies. Enabling New Drug Development for Many Cancers - Discovery of abnormalities in cancer growth proteins leading to the development of successful drugs including a 42% increase in survival for some people with advanced lung cancer, and a 63% improvement in survival for certain types of metastatic melanoma. The Kinome Project, with initial Barr Program funding in 1997, discovered mutations in a family of genes called kinases that prevent cell growth stimulators from being turned off, resulting in cancer cells that replicate uncontrollably. These discoveries by William Sellers, MD, and his colleagues led directly to the development of targeted drugs used by patients worldwide for the treatment of multiple cancers including lung cancer, leukemia, and melanoma. Examples include Tarceva and Vemurafenib, which improve survival in subsets of people with lung cancer and melanoma, respectively. This work has become the model for personalized medicine in cancer treatment and is widely credited for helping transform the approach that pharmaceutical companies use for drug development. Obesity and Cancer: Discovering Critical Linkages - Determining why obesity is a risk factor for cancer, leading to the potential for major breakthroughs in the development of new ways to treat and prevent cancer. Bruce Spiegelman, PhD, supported by the Barr Program in 2005, has demonstrated that obesity causes many body-wide alterations in metabolism, hormone levels, and inflammation, and that these abnormalities may affect the development and progression of cancers. Determining the link between obesity and these cancers could be instrumental to inhibiting cancer development in both obese and non-obese people. Immune Therapies Enabling the Body to Fight Cancer - Enabling the discovery and successful use of vaccines to enhance the ability of the human immune system to attack cancers, including an increase in survival for men with prostate cancer. Shannon Turley, PhD, discovered a new class of cells that suppress immune responses against cancer. With Barr funding awarded in 2008, Dr. Turley used mouse models to understand how

3 some of the most difficult cancers to treat, such as pancreatic cancer, are able to suppress immune responses. This growing understanding of the process is enabling development of new treatments, such as the prostate cancer vaccine Provenge, which enhances the immune system s ability to attack prostate cancers. New Ways to Activate the Immune System - Enabling the development of new vaccines and other approaches that enhance the immune system s response to cancers. An important area of cancer research asks why humans don t reject tumors in their own bodies. Funded by the Barr Program in 1998, Glenn Dranoff, MD, discovered complex regulatory pathways in the human immune system that cancers exploit in order to escape destruction. Reversal of these effects can lead to the development of vaccines against cancer, like Provenge for prostate cancer. This Barr research has also enabled the development of immune activators for melanoma and other cancers. A recent example is Ipilimumab, which showed striking effects in melanoma in a trial led by Dana-Farber scientists and is now approved by the FDA. Leukemia and Lymphoma Blocking Key Drivers of Cancer Cell Growth - Discovery of mutations in genes that modify RNA, leading to a new understanding of Chronic Lymphocytic Leukemia (CLL), the most common of adult leukemias. Chronic lymphocytic leukemia (CLL) causes a slow increase in white blood cells called B lymphocytes, or B cells. Cancer cells spread through the blood and bone marrow, and can also affect the lymph nodes or other organs such as the liver and spleen. CLL eventually causes the bone marrow to fail. Funded by the Barr Program in , Cathy Wu, MD, used powerful next generation DNA sequencing to identify five genes that are abnormal in CLL. The numerous genetic flaws uncovered by the search could not only aid in the prediction of disease course but also offer clues to the biological underpinnings of CLL, paving the way for novel targeted treatments. Improving Treatment Potency - Identifying genes in leukemias and lymphomas that cause resistance to treatment. Although our current therapies cure about half of all patients with leukemia and lymphoma, the other half fail treatment because their diseases become resistant to treatment. This often happens as a result of genetic alterations in their leukemia and lymphoma cells. Barr funding in and has allowed David Weinstock, MD, (a DFMC runner/fundraiser in 2013 and 2014) to use powerful new technologies to identify the genes that can cause this kind of resistance. Drugs that inactivate these genes could prevent resistance and lead to cures in many more patients. New Drugs to Trigger Cancer Cell Death - Development of new therapies that reactivate the ability of cancer cells to die. All living cells contain executioner proteins that help control the growth of normal cells. Cancer cells find a way to prevent activation of these proteins, enabling them to replicate uncontrollably. The 2008 Barr research project of Loren Walensky, MD, PhD, generated novel compounds that bind to these proteins in cancer cells, reactivating their executioner function and triggering cell death. By integrating chemistry, biology, and cancer medicine, this work has the potential to create

4 groundbreaking new therapies for multiple types of cancer, many of which no longer respond to conventional therapies. Lung Cancer Discovery of an Important Mutation - Discovery of mutations in the protein EGFR leading to a 42% increase worldwide in survival for patients with these mutations. Lung cancer claims more lives than any other cancer, and is extremely difficult to treat. The Barr Program provided the initial funding in 2002 to Matthew Meyerson, MD, PhD, who discovered mutations in the protein EGFR in certain lung cancer tumors. This discovery defined the patients who benefit from Tarceva and other drugs that target EGFR in the 15% of lung cancer patients whose tumors contain these mutations. Today, these drugs are being used successfully across the world to help people with cancers that were previously untreatable. Dr. Meyerson ran the Boston Marathon in 2011 as a member of the Dana-Farber Marathon Challenge fundraising team. New Treatments for Drug-Resistant Cancers - Development of new compounds, potentially the next superdrugs, to treat some of the most resistant cancers. One of the difficult problems facing cancer physicians is the ability of tumors to become resistant to therapies that are initially effective. A most promising area of cancer therapeutics is using chemistry for basic research to design and create new classes of compounds that bind to and inhibit the growth of cancer cells that have become drug-resistant. In 2006, Michael Eck, MD, PhD, and Nathanael Gray, PhD, received Barr funding to uncover structural characteristics of cancer cells and to develop compounds that attach themselves to these structures in a way that inhibits their growth. This work is leading to the development of new drugs that are effective against resistant cancers. Recently, they identified ways to overcome resistance to a new class of lung cancer drugs, known as EGFR inhibitors. Pharmaceutical companies quickly developed new drugs based on their work, and one of these drugs was shown to improve the survival of people with lung cancer who have resistance to older EGFR inhibitors. Speeding New Drug Development - Discovery of a new clinical trial approach, called co-clinical trials, enabling the use of animal models to much more accurately predict behavior of treatments in humans for lung cancers. Kwok-Kin Wong, MD, PhD, used Barr funding in to turbocharge the process of cancer drug testing. Clinical trials of anti-cancer drugs usually show that they are effective in only a subset of tested patients. Identifying which patients can benefit from a drug is difficult to achieve but can spare those who won t benefit from treatment. This saves time in drug development and health care dollars. Dr. Wong conducted a clinical trial of two drugs in patients while simultaneously testing the drugs in genetically modified mice he had developed. The responses in mice allowed Dr. Wong to develop a genetic profile that perfectly predicted who would respond in the clinical trial. Dr. Wong is developing similar co-clinical trials to test drugs with pharmaceutical companies around the world.

5 Pancreatic Cancer Enabling More Effective Diagnosis and Treatment - Creation of the first mouse model that faithfully replicates the genetic profile of human pancreatic cancer, one of the most lethal cancers that affects nearly 44,000 people annually. Pancreatic cancer remains one of the most difficult cancers to treat. There is no early diagnostic test for pancreatic cancer, and genetic research has done little to improve patient outcomes. Nabeel Bardeesy, PhD, used Barr funding in 2003 to develop the world s first authentic mouse model of pancreatic cancer. This enabled the detailed study of genes most likely to drive the progression of pancreatic cancer in humans. Dr. Bardeesy s work is now being leveraged by other cancer institutes and drug companies to identify and test new treatments. New Treatments - Discovery that hydroxychloroquine, currently used for treating malaria, is effective in shrinking or slowing the growth of pancreatic cancers. Hydroxychloroquine is a drug that inhibits autophagy, a process that enables cells to break down and eliminate structures such as damaged cell membranes. Cancer cells use autophagy to outwit chemotherapy treatment: by activating this process they survive the stress of therapy. Alec Kimmelman, MD, PhD, with Barr Program support in , discovered that autophagy is turned on at all times in pancreatic cancer cells, suggesting that pancreas tumors are highly dependent on autophagy and therefore good candidates for autophagy-inhibiting treatments. Testing with mice treated with the drug, the treatments were found to be very effective, and Dr. Kimmelman is advancing this discovery into human trials. Pediatric Cancers Neuroblastoma in Children: New Treatment - Discovery that about 10% of pediatric neuroblastoma tumors contain a specific mutation, leading to the possible use of drugs that have already proven successful in treating other cancers that have the same mutation. Neuroblastoma has historically been a very difficult cancer to treat in children, and, although chemotherapy and stem cell transplants have improved survival, relapse is common and nearly almost always fatal. With Barr support in 2007, Rani George, MD, PhD, discovered that a significant number of neuroblastoma tumors contain a mutation in the gene ALK. Several successful drugs already exist to treat other types of cancer that demonstrate these same ALK mutations, and Dr. George and her team have initiated clinical trials that could result in new treatments that will improve survival for children with neuroblastoma. Personalized Medicine Optimizing Treatment of Early Stage Cancers - Determining which of the 35% of early-stage breast cancer patients should receive chemotherapy and sparing the other 65% from unnecessary treatments. We now know that not all tumors are alike, and that treatment strategies need to be based on the unique molecular characteristics of each cancer not just the organs where tumors originate.

6 Funded by the Barr Program in 1996, Todd Golub, MD, performed one of the first molecular classifications of tumors, which are now used by oncologists around the world to personalize treatment decisions for people with cancer. For example, gene expression is now used routinely to help determine which people with breast cancer are most likely to relapse after surgery and therefore need additional treatment. Determining When to Use Chemotherapy - Discovery of a new test to determine whether specific cancer cells will die from chemotherapy, enabling a better way to determine which patients will benefit from chemotherapy. Normal cells of the body are constructed so that if they become sufficiently damaged or abnormal, they rapidly die through a process known as apoptosis before they can cause any harm. Cancer cells, which bear many abnormalities, apparently have found ways to escape this death sentence through antideath proteins. Anthony Letai, MD, PhD, used Barr Program funds in 2005 to develop a test to determine whether a patient s specific cancer cells will be killed by chemotherapy, thereby enabling the selection of the most appropriate treatment. Dr. Letai is currently commercializing this test to make it available for a range of different types of cancer. Supportive Care Pain Management: New Treatment Opportunities - Discovery of the underlying genes responsible for the crippling neuropathic pain experienced by more than 30% of all cancer patients, leading to new approaches for the development of drugs that treat pain. Managing the pain that some people with cancer experience as a result of their disease and from the side effects of treatments is an area in which little progress has been made. With Barr support in 2007, Quifu Ma, PhD, revolutionized the understanding of this problem by identifying genes expressed in neurons that are critical for pain perception. Eventually, this will enable drug companies to develop novel therapeutic targets for pain treatment.

CANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients

CANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING

More information

SU2C TOP SCIENCE ACCOMPLISHMENTS

SU2C TOP SCIENCE ACCOMPLISHMENTS SU2C TOP SCIENCE ACCOMPLISHMENTS INTRODUCTION Since our founding in 2008, Stand Up To Cancer has funded 87 team science projects, with budgets ranging from $250,000 for a short research project to over

More information

A report on the Pediatric Low-Grade Astrocytoma (PLGA) Program Prepared for the Lauren s First and Goal Foundation August 6, 2013

A report on the Pediatric Low-Grade Astrocytoma (PLGA) Program Prepared for the Lauren s First and Goal Foundation August 6, 2013 A report on the Pediatric Low-Grade Astrocytoma (PLGA) Program Prepared for the Lauren s First and Goal Foundation August 6, 2013 EXECUTIVE SUMMARY Over the past several years, the Pediatric Low Grade

More information

New Developments in Cancer Treatment. Dulcinea Quintana, MD

New Developments in Cancer Treatment. Dulcinea Quintana, MD New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4

More information

Children s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant

Children s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant Children s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant Reporting Period January 1, 2012 June 30, 2012 Formula Grant Overview The Children s Hospital of Philadelphia received $3,521,179

More information

Welcome! Here s our agenda for today:

Welcome! Here s our agenda for today: Welcome! Here s our agenda for today: What is ovarian cancer? What causes it? When does genetic testing come in? When are families at risk for ovarian cancer? What are the treatments? 3 things to remember

More information

PROGRESS UPDATE. The Prayers From Maria Foundation

PROGRESS UPDATE. The Prayers From Maria Foundation PROGRESS UPDATE The Prayers From Maria Foundation August 2016 EXECUTIVE SUMMARY Dana-Farber Cancer Institute is a global leader in discovery science and patient care for pediatric brain tumors, including

More information

Accelerate Your Research with Conversant Bio

Accelerate Your Research with Conversant Bio Imagination has given us the steam engine, the telephone, the talkingmachine and the automobile, for these things had to be dreamed of before they became realities. So I believe that dreams... are likely

More information

Targeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009

Targeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009 Targeted Medicine and Molecular Therapeutics Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009 Approaches to Cancer Prevention Screening and early diagnosis

More information

Restoration. JDRF is turning Type One into Type None. attack so the newly restored beta cell function is protected.

Restoration. JDRF is turning Type One into Type None. attack so the newly restored beta cell function is protected. Restoration JDRF is turning Type One into Type None Type 1 diabetes (T1D) is an extraordinarily complex disease. Finding the cure a short-term clinical intervention, with minimal side effects, after which

More information

New Developments in Cancer Treatment. Ian Rabinowitz MD

New Developments in Cancer Treatment. Ian Rabinowitz MD New Developments in Cancer Treatment Ian Rabinowitz MD Treatment Outline Angiogenesis inhibition Targeted therapy Immunotherapy Personalization of therapy Genomics and cancer Stem cells and cancer Angiogenesis

More information

PROGRESS UPDATE. Lauren s First and Goal

PROGRESS UPDATE. Lauren s First and Goal PROGRESS UPDATE Lauren s First and Goal August 2015 EXECUTIVE SUMMARY The Pediatric Low-Grade Astrocytoma (PLGA) Program at Dana-Farber Cancer Institute is committed to improving outcomes for young patients

More information

Acute: Symptoms that start and worsen quickly but do not last over a long period of time.

Acute: Symptoms that start and worsen quickly but do not last over a long period of time. Cancer Glossary Acute: Symptoms that start and worsen quickly but do not last over a long period of time. Adjuvant therapy: Treatment given after the main treatment. It usually refers to chemotherapy,

More information

Thomas C. Wilmot, Sr. Judy Wilmot Linehan

Thomas C. Wilmot, Sr. Judy Wilmot Linehan Thomas C. Wilmot, Sr. Judy Wilmot Linehan The Wilmot Family For more than 35 years, the Wilmot family has been dedicated to supporting cancer research and care for the Rochester community. Their generosity

More information

Question #1 Controls on cell growth and division turned on and off

Question #1 Controls on cell growth and division turned on and off Lesson Overview 10.3 Regulating the Cell Cycle Question #1 Controls on cell growth and division turned on and off When cells are grown in the laboratory, most cells will divide until they come into contact

More information

Oncology 101. Cancer Basics

Oncology 101. Cancer Basics Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases

More information

Cancer Cells. It would take another 20 years and a revolution in the techniques of biological research to answer these questions.

Cancer Cells. It would take another 20 years and a revolution in the techniques of biological research to answer these questions. Cancer Cells Cancer, then, is a disease in which a single normal body cell undergoes a genetic transformation into a cancer cell. This cell and its descendants, proliferating across many years, produce

More information

Chapter 10-3 Regulating the Cell Cycle

Chapter 10-3 Regulating the Cell Cycle Chapter 10-3 Regulating the Cell Cycle Vocabulary: Cyclin Cancer Key Concepts: How is the cell cycle regulated? How are cancer cells different from other cells? I. Introduction A. An Interesting Fact About

More information

An update on your support of the Kaplan Cancer Research Fund Swedish Cancer Institute

An update on your support of the Kaplan Cancer Research Fund Swedish Cancer Institute An update on your support of the Swedish Cancer Institute At Swedish, we re committed to offering our patients the newest, most innovative cancer treatment available. Through your support of the at the

More information

PROGRESS UPDATE. Evan T. Mandeville DIPG Research Fund

PROGRESS UPDATE. Evan T. Mandeville DIPG Research Fund PROGRESS UPDATE Evan T. Mandeville DIPG Research Fund December 2018 EXECUTIVE SUMMARY As a top-ranked pediatric cancer center, Dana-Farber Cancer Institute combines first-rate patient care with groundbreaking

More information

Biological Therapies for Cancer: Questions and Answers

Biological Therapies for Cancer: Questions and Answers Biological Therapies for Cancer: Questions and Answers Key Points Biological therapies use the body s immune system to fight cancer or to lessen the side effects that may be caused by some cancer treatments

More information

Lecture 1: Carcinogenesis

Lecture 1: Carcinogenesis Lecture 1: Carcinogenesis Anti-cancer (oncology agents): These are perhaps the most dangerous of drugs, other than the narcotic analgesics. This is due to their toxicities. Killing or inhibiting cancer

More information

March 2018 (i2i-18) Competition Awarded Innovation to Impact Grants Listed by panel in alphabetical order

March 2018 (i2i-18) Competition Awarded Innovation to Impact Grants Listed by panel in alphabetical order I1a March 2018 (i2i-18) Competition Awarded Innovation to Impact Grants Listed by panel in alphabetical order Biomarkers and Genomics Brooks-Wilson, Angela Genetic buffering in cancer The risk of many

More information

Addressing Breast Cancer's High Recurrence Rates: The Breast Cancer Translational Center of Excellence (TCE)

Addressing Breast Cancer's High Recurrence Rates: The Breast Cancer Translational Center of Excellence (TCE) Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/addressing-breast-cancershigh-recurrence-rates-breast-cancer-translational-center-excellence-tce/7981/

More information

Camel Milk and Cancer: A Possible Cure?

Camel Milk and Cancer: A Possible Cure? Camel Milk and Cancer: A Possible Cure? You may have heard that camel milk has many amazing therapeutic benefits, but did you know that it also has anti-cancer properties? In 2016 it was estimated that

More information

Information. about cancer

Information. about cancer 1 Information about cancer This chapter may help you answer simple questions about what cancer is and how it is treated. There are more than 200 different types of cancer and a range of treatments. Being

More information

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand

More information

Calquence. Calquence (acalabrutinib) Description

Calquence. Calquence (acalabrutinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.106 Subject: Calquence Page: 1 of 5 Last Review Date: March 16, 2018 Calquence Description Calquence

More information

PROGRESS UPDATE. A Kids Brain Tumor Cure Foundation

PROGRESS UPDATE. A Kids Brain Tumor Cure Foundation PROGRESS UPDATE A Kids Brain Tumor Cure Foundation September 2016 EXECUTIVE SUMMARY Primary cancers of the brain have surpassed leukemias to become the number one cause of cancer-related death in children.

More information

BLOOD AND LYMPH CANCERS

BLOOD AND LYMPH CANCERS BLOOD AND LYMPH CANCERS 2 Blood and Lymph Cancers Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Kenneth C. Anderson, MD Harvard Medical School and Dana-Farber

More information

CANCER Uncontrolled Cell Division

CANCER Uncontrolled Cell Division CANCER Uncontrolled Cell Division What is cancer? Why does it occur? Where does it occur? Benign vs. Malignant? Types of Cancer (3 main groups) There are over 200 different types of cancer 1) Carcinomas

More information

Asexual Reproduction & Cancer

Asexual Reproduction & Cancer Asexual Reproduction & Cancer Asexual Reproduction Only one individual needed No new genetic material added = organism clones itself Reproduction is fast and produces many individuals Gene pool is shallow

More information

Viruses and cancer: Should we be more afraid?

Viruses and cancer: Should we be more afraid? Viruses and cancer: Should we be more afraid? Viruses and cancer: Should we be more afraid? During the past 30 years it has become exceedingly clear that several viruses play significant roles in the development

More information

P U R D U E U N I V E R S I T Y C E N T E R F O R C A N C E R R E S E A R C H

P U R D U E U N I V E R S I T Y C E N T E R F O R C A N C E R R E S E A R C H A U G U S T 2 0 1 7 P U R D U E U N I V E R S I T Y C E N T E R F O R C A N C E R R E S E A R C H TIM'S TWIGS CANCER RESEARCH PROJECTS I N T R O D U C T I O N The fight against cancer begins in the laboratory

More information

Study of Triple-Negative Breast Cancer is Most Cited in AACR Journal

Study of Triple-Negative Breast Cancer is Most Cited in AACR Journal MEDIA CONTACT: Craig Civale Craig.Civale@BaylorHealth.edu (817)709-7067 Study of Triple-Negative Breast Cancer is Most Cited in AACR Journal TGen, Baylor, US Oncology study revealed therapeutic drug targets

More information

Emerging Targets in Immunotherapy

Emerging Targets in Immunotherapy Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy

More information

Radical treatment for leukemia under way 17 January 2011, By Fumihiko Ishikawa

Radical treatment for leukemia under way 17 January 2011, By Fumihiko Ishikawa Radical treatment for leukemia under way 17 January 2011, By Fumihiko Ishikawa Figure 1: Major blood cells that differentiate from hematopoietic stem cells. Hematopoietic stem cells differentiate into

More information

- A cancer is an uncontrolled, independent proliferation of robust, healthy cells.

- A cancer is an uncontrolled, independent proliferation of robust, healthy cells. 1 Cancer A. What is it? - A cancer is an uncontrolled, independent proliferation of robust, healthy cells. * In some the rate is fast; in others, slow; but in all cancers the cells never stop dividing.

More information

Overview of Cancer. Mylene Freires Advanced Nurse Practitioner, Haematology

Overview of Cancer. Mylene Freires Advanced Nurse Practitioner, Haematology Overview of Cancer Mylene Freires Advanced Nurse Practitioner, Haematology Aim of the Presentation Review basic concepts of cancer Gain some understanding of the socio-economic impact of cancer Order of

More information

DR. RAMESH U2 L4 MITOSIS AND CANCER

DR. RAMESH U2 L4 MITOSIS AND CANCER DR. RAMESH U2 L4 MITOSIS AND CANCER Objective! The student will (TSW) identify the relationship between cancer and mitosis. Benchmark/Standard LS-H-B2: Compare mitosis and meiosis Why are we learning this?!

More information

Researching Cancer Medicines: Setbacks and Stepping Stones

Researching Cancer Medicines: Setbacks and Stepping Stones Researching Cancer Medicines: Setbacks and Stepping Stones Researching Cancer Medicines: Setbacks and Stepping Stones 2 Executive Summary 3 Introduction 4 The Human Burden 5 The Economic Burden 6 Understanding

More information

Action, Not Awareness Breast Cancer Awareness Month National Breast Cancer Coalition Advocate Toolkit

Action, Not Awareness Breast Cancer Awareness Month National Breast Cancer Coalition Advocate Toolkit Action, Not Awareness National Breast Cancer Coalition Advocate Toolkit 2 INTRODUCTION Awareness of breast cancer is at an all-time high. Yet breast cancer still kills almost as many Americans each year

More information

Giving Opportunities Center for Regenerative Medicine $5 million

Giving Opportunities Center for Regenerative Medicine $5 million Beyond Extraordinary Giving Opportunities Name Center for Regenerative Medicine Leukemia Center of Excellence Lymphoma Center of Excellence Multiple Myeloma Center of Excellence The Infusion Treatment

More information

Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia (CLL) Page 1 of 10 PATIENT EDUCATION Chronic Lymphocytic Leukemia (CLL) Introduction Chronic lymphocytic leukemia (CLL) is a type of cancer of the lymphocytes (a kind of white blood cell). It is also referred

More information

Cancer and Gene Alterations - 1

Cancer and Gene Alterations - 1 Cancer and Gene Alterations - 1 Cancer and Gene Alteration As we know, cancer is a disease of unregulated cell growth. Although we looked at some of the features of cancer when we discussed mitosis checkpoints,

More information

Melatonin and its Role in the Inhibition of Breast Cancer Ciara Nicol Ross Copyright 2014 by Ciara Ross and Koni Stone

Melatonin and its Role in the Inhibition of Breast Cancer Ciara Nicol Ross Copyright 2014 by Ciara Ross and Koni Stone 1 Melatonin and its Role in the Inhibition of Breast Cancer Ciara Nicol Ross Copyright 2014 by Ciara Ross and Koni Stone Cancer is a disease caused by out of control division of abnormal cells within a

More information

Immunology Lecture 4. Clinical Relevance of the Immune System

Immunology Lecture 4. Clinical Relevance of the Immune System Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor

More information

Cancer arises from the mutation of a normal gene. A factor which brings about a mutation is called a mutagen.

Cancer arises from the mutation of a normal gene. A factor which brings about a mutation is called a mutagen. Cancer Single cells divide by mitosis to form many cells. This cells undergo physical and chemical changes in order to perform specific functions. (we say the cells have Differentiated) in this way we

More information

Cancer. October is National Breast Cancer Awareness Month

Cancer. October is National Breast Cancer Awareness Month Cancer October is National Breast Cancer Awareness Month Objectives 1: Gene regulation Explain how cells in all the different parts of your body develop such different characteristics and functions. Contrast

More information

Introduction to Targeted Therapy

Introduction to Targeted Therapy Introduction to Targeted Therapy Cancer remains the second leading cause of death in the United States, despite the significant advances in cancer therapy made over the past several decades. Many factors

More information

The Wistar Institute is an international leader in biomedical

The Wistar Institute is an international leader in biomedical A LEADER IN RESEARCH The Wistar Institute is an international leader in biomedical research with special expertise in cancer, immunology and infectious disease research. The Institute works actively to

More information

The Future of Cancer. Lawrence Tsui Global Risk Products Actuary Swiss Reinsurance Company Hong Kong. Session Number: WBR8

The Future of Cancer. Lawrence Tsui Global Risk Products Actuary Swiss Reinsurance Company Hong Kong. Session Number: WBR8 Lawrence Tsui Global Risk Products Actuary Swiss Reinsurance Company Hong Kong Session Number: WBR8 Agenda Cancer the basics Cancer past and present Cancer the future CANCER THE BASICS Cancer the basics

More information

BIT 120. Copy of Cancer/HIV Lecture

BIT 120. Copy of Cancer/HIV Lecture BIT 120 Copy of Cancer/HIV Lecture Cancer DEFINITION Any abnormal growth of cells that has malignant potential i.e.. Leukemia Uncontrolled mitosis in WBC Genetic disease caused by an accumulation of mutations

More information

Lecture 1: Carcinogenesis

Lecture 1: Carcinogenesis Lecture 1: Carcinogenesis Anti-cancer (oncology agents): These are perhaps the most dangerous of drugs, other than the narcotic analgesics. This is due to their toxicities. Killing or inhibiting cancer

More information

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells

More information

Grand Challenge and other funding opportunities at Cancer Research UK. Jamie Meredith, 9 th Dec 15

Grand Challenge and other funding opportunities at Cancer Research UK. Jamie Meredith, 9 th Dec 15 Grand Challenge and other funding opportunities at Cancer Research UK Jamie Meredith, 9 th Dec 15 Multidisciplinary research at CRUK OVERVIEW About CRUK CRUKs research strategy A focus on multidisciplinary

More information

INTRODUCTION PREVIOUSLY FUNDED PROJECTS

INTRODUCTION PREVIOUSLY FUNDED PROJECTS INTRODUCTION Each year in the United States, more than 1.6 million people are diagnosed with cancer and more than half a million die from this terrible disease. And each year, our researchers spend thousands

More information

First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor

First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented

More information

Patient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017

Patient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017 Patient Leader Education Summit Precision Medicine: Today and Tomorrow March 31, 2017 Precision Medicine: Presentation Outline Agenda What is a Precision Medicine What is its clinical value Overview of

More information

CAR-T Cell Therapy: A Breakthrough Treatment for Fighting Cancer

CAR-T Cell Therapy: A Breakthrough Treatment for Fighting Cancer Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/car-t-cell-therapy-abreakthrough-treatment-for-fighting-cancer/9859/

More information

through the cell cycle. However, how we administer drugs also depends on the combinations that we give and the doses that we give.

through the cell cycle. However, how we administer drugs also depends on the combinations that we give and the doses that we give. Hello and welcome to this lecture. My name is Hillary Prescott. I am a Clinical Pharmacy Specialist at The University of Texas MD Anderson Cancer Center. My colleague, Jeff Bryan and I have prepared this

More information

The Nobel Assembly at Karolinska Institutet. has today decided to award. the 2018 Nobel Prize in Physiology or Medicine.

The Nobel Assembly at Karolinska Institutet. has today decided to award. the 2018 Nobel Prize in Physiology or Medicine. The Nobel Assembly at Karolinska Institutet has today decided to award the 2018 Nobel Prize in Physiology or Medicine jointly to James P. Allison and Tasuku Honjo for their discovery of cancer therapy

More information

Opdivo. Opdivo (nivolumab) Description

Opdivo. Opdivo (nivolumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:

More information

Targeted Cancer Therapies: Questions and Answers. Key Points

Targeted Cancer Therapies: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Targeted Cancer Therapies:

More information

IMMUNOTHERAPY FOR LUNG CANCER

IMMUNOTHERAPY FOR LUNG CANCER IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Lung Cancer Basics... 2 Immunotherapy... 3 FDA Approved Immunotherapies...

More information

Genomic explorations have offered us a great deal. Buried Treasure

Genomic explorations have offered us a great deal. Buried Treasure 18 Buried Treasure Noncoding DNA makes up the majority of our genomes, much of it being conserved and transcribed. Though the functions of small regulatory RNA molecules are well known, what about so-called

More information

Blood Cancer: Chronic Myelogenous Leukaemia

Blood Cancer: Chronic Myelogenous Leukaemia Published on: 30 May 2017 Blood Cancer: Chronic Myelogenous Leukaemia What Is Cancer? The body is made up of cells that grow and die in a controlled way. Sometimes, cells keep dividing and growing without

More information

Personalized Therapies for Lung Cancer. Questions & Answers

Personalized Therapies for Lung Cancer. Questions & Answers Personalized Therapies for Lung Cancer Questions & Answers What are Personalized Therapies for lung cancer? Like people, no two lung cancer tumors are the same. Personalized medicine (also known as precision

More information

Progress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader:

Progress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader: SU2C -Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant: DNA Repair Therapies for Ovarian Cancer AND SU2C Catalyst Merck-Supported Supplemental

More information

Health Systems Adoption of Personalized Medicine: Promise and Obstacles. Scott Ramsey Fred Hutchinson Cancer Research Center Seattle, WA

Health Systems Adoption of Personalized Medicine: Promise and Obstacles. Scott Ramsey Fred Hutchinson Cancer Research Center Seattle, WA Health Systems Adoption of Personalized Medicine: Promise and Obstacles Scott Ramsey Fred Hutchinson Cancer Research Center Seattle, WA Cancer Pharmaceutical Pricing Bach P. NEJM 2009;360:626 Opportunities

More information

Chapter 40 Section 2 The Immune System

Chapter 40 Section 2 The Immune System Chapter 40 Section 2 The Immune System Science Standard 10a What is the role of the skin in providing nonspecific defenses against infection? What is the function of the immune system? The immune system

More information

GENE THERAPY AS A SOLUTION TO SICKLE CELL DISEASE

GENE THERAPY AS A SOLUTION TO SICKLE CELL DISEASE GENE THERAPY AS A SOLUTION TO SICKLE CELL DISEASE Introduction The genetic disease I have chosen is sickle cell disease. The aim of this study is to investigate the use of gene therapy as a scientific

More information

ANIMAL RESEARCH IS HELPING TO BEAT CANCER SOONER

ANIMAL RESEARCH IS HELPING TO BEAT CANCER SOONER ANIMAL RESEARCH IS HELPING TO BEAT CANCER SOONER WHAT WE DO Our vision is to bring forward the day when all cancers are cured. Today 2 in 4 patients in the UK survive cancer. Thousands of people are alive

More information

KEY CONCEPT Cells have distinct phases of growth, reproduction, and normal functions.

KEY CONCEPT Cells have distinct phases of growth, reproduction, and normal functions. 5.1 The Cell Cycle KEY CONCEPT Cells have distinct phases of growth, reproduction, and normal functions. Objective: Cells have distinct phases of growth, reproduction and normal functions. APK: Why do

More information

PROGRESS UPDATE. Evan T. Mandeville DIPG Research Fund

PROGRESS UPDATE. Evan T. Mandeville DIPG Research Fund PROGRESS UPDATE Evan T. Mandeville DIPG Research Fund October 2017 EXECUTIVE SUMMARY Investigators at Dana-Farber Cancer Institute are global leaders in pediatric brain tumor research and patient care,

More information

Breast Cancer Diagnosis, Treatment and Follow-up

Breast Cancer Diagnosis, Treatment and Follow-up Breast Cancer Diagnosis, Treatment and Follow-up What is breast cancer? Each of the body s organs, including the breast, is made up of many types of cells. Normally, healthy cells grow and divide to produce

More information

APPENDIX "C" COMPANY DEVELOPMENT PIPELINE

APPENDIX C COMPANY DEVELOPMENT PIPELINE Horse Horse APPENDIX "C" COMPANY DEVELOPMENT PIPELINE Animal Cancer Vaccines AUTOLOGOUS Preclinical Approval ALLOGENEIC Preclinical Approval DIRECT INJECTION Preclinical Approval Horse Q4 2016 Human Cancer

More information

Episode 93: What Role Stem Cells in Leukaemia?

Episode 93: What Role Stem Cells in Leukaemia? Published on Up Close (https://upclose.unimelb.edu.au) Episode 93: What Role Stem Cells in Leukaemia? What Role Stem Cells in Leukaemia? VOICEOVER Welcome to Up Close, the research, opinion and analysis

More information

Regulating the Cell Cycle. Lesson Overview THINK ABOUT IT. How do cells know when to divide? Review: Why do cells divide?

Regulating the Cell Cycle. Lesson Overview THINK ABOUT IT. How do cells know when to divide? Review: Why do cells divide? THINK ABOUT IT How do cells know when to divide? Review: Why do cells divide? Controls on Cell Division How is the cell cycle regulated? The cell cycle is controlled by regulatory proteins both inside

More information

LESSON 3.2 WORKBOOK. How do normal cells become cancer cells? Workbook Lesson 3.2

LESSON 3.2 WORKBOOK. How do normal cells become cancer cells? Workbook Lesson 3.2 For a complete list of defined terms, see the Glossary. Transformation the process by which a cell acquires characteristics of a tumor cell. LESSON 3.2 WORKBOOK How do normal cells become cancer cells?

More information

Cancer. Chapter 31 Lesson 2

Cancer. Chapter 31 Lesson 2 Cancer Chapter 31 Lesson 2 Tumors All cancers are tumors- masses of tissue. Not all tumors are cancers. Some tumors are benign- noncancerous. These tumors are surrounded by membranes that prevent them

More information

Fast-Forwarding a Cure for Melanoma

Fast-Forwarding a Cure for Melanoma Fast-Forwarding a Cure for Melanoma Vision Targeting an Urgent Problem Melanoma often starts out small, misleadingly insignificant a change in a mole, a mark on a fingernail. But the consequences can be

More information

CARDIFF RESEARCH OPEN DAY FOCUS ON CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)

CARDIFF RESEARCH OPEN DAY FOCUS ON CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) CARDIFF RESEARCH OPEN DAY FOCUS ON CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) Saturday 13 October 2012 University Hospital of Wales, Cardiff EXCITING TIMES FOR RESEARCH INTO CHRONIC LYMPHOCYTIC LEUKAEMIA Leukaemia

More information

UCI. Anti-Cancer Challenge Impact report. #weareanticancer

UCI. Anti-Cancer Challenge Impact report. #weareanticancer UCI Anti-Cancer Challenge 2017 Impact report #weareanticancer Your support of the UCI Anti-Cancer Challenge is planting the seeds from which UCI research will grow to improve cancer therapies! As Orange

More information

Type1 Diabetes Cure Research & Autoimmune Diseases

Type1 Diabetes Cure Research & Autoimmune Diseases Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/type1-diabetes-cure-research-autoimmunediseases/1772/

More information

What is Cancer? Understanding the basics of

What is Cancer? Understanding the basics of What is Cancer? Understanding the basics of A process of physical and biological changes that occur when normal healthy cells are transformed into cancer cells What is Cancer? Cancer is an umbrella term

More information

What s the Latest in Prostate Cancer Immunotherapy Options?

What s the Latest in Prostate Cancer Immunotherapy Options? What s the Latest in Prostate Cancer Immunotherapy Options? Jeri Kim, MD Associate Professor, Department of Geritourinary Medical Oncology The University of Texas MD Anderson Cancer Center Sumit K. Subudhi,

More information

SHEDDING A LITTLE LIGHT ON THE BIGGER PROBLEM

SHEDDING A LITTLE LIGHT ON THE BIGGER PROBLEM NationalPCF.org SHEDDING A LITTLE LIGHT ON THE BIGGER PROBLEM 1.7 MILLION NEW CANCER CASES EVERY YEAR 600,000 PEOPLE WILL DIE More than of those who survive childhood cancer will have a significant health

More information

HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS HLH ADULTS & Young People

HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS HLH ADULTS & Young People HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS HLH ADULTS & Young People Histiocytosis UK Introduction Despite the misery it causes, Histiocytosis is too rare a disease to have generated substantial research in medical

More information

CANCER HAS BEEN AROUND

CANCER HAS BEEN AROUND For decades, drug companies have been spending billions of dollars and countless hours on researching and developing treatments and cures for cancer. The reason is easy to understand. Cancer is the second-leading

More information

Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.

Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis. Cancer Biology Chapter 18 Eric J. Hall., Amato Giaccia, Radiobiology for the Radiologist Introduction Tissue homeostasis depends on the regulated cell division and self-elimination (programmed cell death)

More information

NON- HODGKIN LYMPHOMA

NON- HODGKIN LYMPHOMA NON- HODGKIN LYMPHOMA non - Hodgkin lymphoma This medical guide is designed for educational purposes to help patients understand. Please consult your doctor on specific questions and details about your

More information

Date: Wednesday, 26 October :00PM. Location: Museum of London

Date: Wednesday, 26 October :00PM. Location: Museum of London The Treatment of Cancer Transcript Date: Wednesday, 26 October 2016-6:00PM Location: Museum of London 26 October 2016 The Treatment of Cancer Professor Christopher Whitty Being told you have cancer conjures

More information

Introduction to Basic Oncology

Introduction to Basic Oncology Introduction to Basic Oncology Cancer Cell AHS 102 Med Term Dr. Susie Turner 1/3/13 General Oncology Study of Tumors Neoplasms/Tumors Abnormal growth of new tissue Are either; Benign or Malignant Onc/o

More information

Antibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward

Antibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

Hosts. New Treatments for Cancer

Hosts. New Treatments for Cancer Hosts Anees MD Associate Professor of Surgical Oncology Francine Foss MD Professor of Medical Oncology New Treatments for Cancer Guest Expert: Lieping Chen, MD, PhD United Technologies Corporation Professor

More information

Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer

Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies

More information

HOW TO MAXIMIZE PATIENT RECRUITMENT IN ONCOLOGY TRIALS A BIOPHARMA DIVE PLAYBOOK

HOW TO MAXIMIZE PATIENT RECRUITMENT IN ONCOLOGY TRIALS A BIOPHARMA DIVE PLAYBOOK HOW TO MAXIMIZE PATIENT RECRUITMENT IN ONCOLOGY TRIALS A BIOPHARMA DIVE PLAYBOOK Over the last several decades, patient recruitment for clinical trials has remained a major barrier to rapid execution of

More information

Breast Cancer: Who Gets It? Who Survives? The Latest Information

Breast Cancer: Who Gets It? Who Survives? The Latest Information Breast Cancer: Who Gets It? Who Survives? The Latest Information James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine

More information